Drug intelligence / Profile preview

XTR010

Development stage: Unknown
Lead developer: Sinotau Pharmaceutical Group
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

XTR010 is a lutetium-177 (177Lu)-labeled radioligand therapy targeting prostate-specific membrane antigen (PSMA), developed by Sinotau Pharmaceutical Group for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug utilizes a structurally optimized targeting ligand designed to enhance tumor uptake and retention while potentially requiring a lower radionuclide dose compared to existing therapies like Pluvicto (177Lu-PSMA-617). This optimization aims to provide a cost-effective treatment option with comparable or improved therapeutic outcomes. XTR010 was the first domestically developed PSMA-targeted radiopharmaceutical to receive IND approval in China and is currently in Phase I/II clinical development.

Other names: 177Lu-XTR010

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on XTR010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XTR010.

Explore the full profile